Mural Oncology plc (NASDAQ: MURA) had its price target lowered by analysts at HC Wainwright from $18.00 to $6.00. They now have a "buy" rating on the stock.
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Raymond James from a "strong-buy" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
Mural Oncology plc (NASDAQ: MURA) had its "hold" rating re-affirmed by analysts at Jones Trading.
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer